Medindia

X

Siemens' New S Class Revolutionizes the Paradigm of Ultrasound Workflow Today and Tomorrow

Tuesday, November 27, 2007 General News J E 4
Advertisement
CHICAGO, Nov. 26 At the 93rd Scientific Sessions andAnnual Meeting of the Radiological Society of North America (RSNA) from Nov.25 to 30 at McCormick Place (Booth 7713, Hall B), Siemens Medical Solutions(www.usa.siemens.com/medical) will unveil the ACUSON S2000(TM) ultrasoundplatform, the first system in Siemens' new S Class of ultrasound products. Itwill have capabilities for paradigm-shifting applications such as AcousticRadiation Forced Impulse (ARFI)* imaging and is prepared to integrate SiliconUltrasound++ technology.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070904/SIEMENSLOGO )

"We see ARFI and Silicon Ultrasound as the biggest changes in the industrysince Doppler imaging became clinically useful," said Klaus Hambuchen,president, Siemens Medical Solutions, Ultrasound Division. "The ACUSON S2000system represents the pinnacle of innovative technology, workflow-enhancingclinical applications and state-of-the-art ergonomic design. It is our newpremier general imaging platform that will change the way ultrasound is viewedtoday."

Siemens will also showcase its X Class solutions, which include the ACUSONX150(TM) and ACUSON X300(TM) ultrasound systems, as well as the P Class ofportable solutions with the handheld ACUSON P10(TM) and the laptop-basedACUSON P50(TM) system.

Next Generation Ultrasound

Covering the entire continuum of care from screening to diagnosis totherapy and follow-up, the new ACUSON S2000 ultrasound system will featureapplications across general imaging, including obstetrics and gynecology(OB/GYN), as well as vascular and cardiac imaging.

The ACUSON S2000 is Siemens' new platform for some of the most innovativeultrasound applications, including ARFI, which uses acoustic energy todisplace tissue for a qualitative and quantitative assessment of deep tissuestiffness. Current research suggests that this type of assessment may beuseful for differentiation in abnormalities such as liver tumors or thequantification of fibrosis progression.

The ACUSON S2000 system is also capable of integrating Siemens'groundbreaking Silicon Ultrasound technology, which introduces the firstentirely new class of ultrasound transducers in 40 years. Silicon Ultrasoundtechnology uses the precise semiconductor processing techniques of thecomputer chip industry to create a family of probes that will enablevolumetric 4D imaging in a wide range of applications. With SiliconUltrasound, clinicians will get true isotropic 3D images enabling them to seethe same fine level of detail in each direction that they choose to examinethe imaging data. At RSNA, Siemens will present the power of this approach inbreast imaging and other high-resolution applications.

Additionally, Siemens is preparing the ACUSON S2000 system for AutomatedBreast Scanning (ABS), a technique that provides automated, reproducible 3Dultrasound volumes of the breast. ABS is an important tool in the screening,diagnosis and follow-up care of breast cancer supplementing mammography,especially in women with dense breast tissue. ABS reduces acquisitionvariability and cycle time when compared to manual breast ultrasound, makingit more reproducible and consistent for interpreting physicians.

Increased Clinical Confidence

The ACUSON S2000 ultrasound system improves clinical confidence with anumber of intelligent applications. For instance, Advanced SieClear(TM)spatial compounding uses electronic beam steering to rapidly acquireoverlapping images from different view angles. The technique enhances anatomicborder definition and improves overall tissue contrast.

In combination with Dynamic TCE(TM) tissue contrast enhancement, itfurther reduces speckle/noise and enhances borders. Dynamic TCE can improvesubtle tissue differentiation especially for patients who are technicallydifficult to image. The ACUSON S2000 system will be the first t
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Amedica Receives FDA 510(k) Clearance for Valeo(TM...
S
Human Genome Sciences Invites Investors to Listen ...